Navigation Links
BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
Date:12/6/2011

BOTHELL, Wash., Dec. 6, 2011 /PRNewswire/ -- BioLife Solutions Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary biopreservation media products for cells, tissues, and organs, today announced the launch of its new corporate website that includes the following features:

  • Built on the Genesis Framework for WordPress, which incorporates state of the art code and smart design architecture optimized for search engine visibility, so prospective customers quickly find the website and its biopreservation resources.
  • A free product sample offer (http://biolifesolutions.com/sample/) integrated with automatic lead creation in SalesForce.com, BioLife's cloud based customer relationship management system.
  • An integrated blog updated with customer product experiences and application notes authored by members of BioLife's Scientific Advisory Board, customers, and partners in the field of biopreservation.
  • An updated investor presentation and corporate data sheet.

  • Mike Rice, BioLife Chief Executive Officer, commented on the launch of the Company's new website by stating, "Our new site has been designed to increase awareness and adoption of our high-quality cGMP HypoThermosol, CryoStor, and BloodStor® biopreservation media products.  Many biopreservation practitioners continue to use non-optimized, home-brew cell storage and freeze media formulations.  This integrated free product sample offer should generate future revenue, as nearly all prospects decide to become repeat customers once the superior biopreservation efficacy of our pre-formulated, serum-free, protein-free products is demonstrated during a product comparison."

    BioLife's new website was designed in collaboration with Medical Marcom, a Seattle-based medical device marketing firm, and Two Hour Blogger, a Tulsa-based web design agency.

    (Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

    About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

    This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations: Investor Relations:Len Hall

    Matt ClawsonAllen & Caron Inc

    Allen & Caron Inc(949) 474-4300

    (949) 474-4300len@allencaron.com

    matt@allencaron.com
    '/>"/>

    SOURCE BioLife Solutions, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells
    2. BioLife Solutions CEO Issues 2010 Corporate Update
    3. BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification
    4. BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement
    5. BioLife Solutions Granted Japanese Biopreservation Patent
    6. BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich
    7. BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions
    8. BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement
    9. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
    10. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
    11. Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
    (Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
    (Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
    (Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
    Breaking Biology Technology:
    (Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
    (Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
    (Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
    Breaking Biology News(10 mins):